Divis Laboratories
Divis Laboratories, a leading player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1990, the company has established itself as a prominent manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to a global clientele. With a strong focus on research and development, Divis Laboratories has achieved significant milestones, including the successful launch of several high-quality products that meet stringent regulatory standards. The company’s core offerings include APIs for various therapeutic areas, particularly in anti-retroviral and anti-cancer medications, which are distinguished by their purity and efficacy. Divis Laboratories is recognised for its robust market position, consistently ranking among the top suppliers in the industry. Its commitment to innovation and sustainability further enhances its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Divis Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Divis Laboratories's score of 34 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Divis Laboratories's reported carbon emissions
In 2023, Divis Laboratories, headquartered in India, reported total carbon emissions of approximately 363,246,000 kg CO2e for Scope 1 and 325,972,000 kg CO2e for Scope 2. This follows a similar trend in 2022, where emissions were about 382,670,000 kg CO2e for Scope 1 and 370,742,000 kg CO2e for Scope 2. The company has committed to significant climate action, aiming to reduce its intensity-based greenhouse gas emissions (Scope 1 and Scope 2) by 25% by 2030. Divis Laboratories has also set long-term net-zero targets, committing to achieve net-zero emissions across all scopes by 2050. This commitment aligns with industry standards and reflects the company's dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company’s emissions intensity per rupee of turnover was reported at 0.000084 kg CO2e in 2022, indicating a focus on improving efficiency alongside emissions reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 382,670,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 370,742,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Divis Laboratories is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
